Sermorelin - Dragon Pharma

Sermorelin Acetate, designed as a fragment of the natural growth hormone-releasing hormone (GHRH), was synthesized in the early 1980s and approved by the FDA in 1997 for diagnostic purposes. Marketed under Geref by Serono, it served to evaluate pituitary function and treat children with growth hormone deficiency. Though it was less successful than somatropin, its natural regulation of growth hormone via the body's feedback systems distinguished it. After discontinuation in 2008, compounded versions of the peptide remain in use for specific medical applications.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Sermorelin by Dragon Pharma, consult with your doctor or healthcare professional.